Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Prognostic impact of carboxylesterase 1 gene variants in patients with congestive heart failure treated with angiotensin-converting enzyme inhibitors

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Patients with prolonged effect of succinylcholine or mivacurium had novel mutations in the butyrylcholinesterase gene

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetes

    Research output: Contribution to journalReviewpeer-review

  1. Temporal changes in the incidence of infective endocarditis in Denmark 1997-2017: A nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Atrial fibrillation is a marker of increased mortality risk in non-ischemic heart failure - results from the DANISH Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Work exposure and associated risk of hospitalisation with pneumonia and influenza: A nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Switching from Vitamin K Antagonist to Dabigatran in Atrial Fibrillation: Differences According to Dose

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Most angiotensin-converting enzyme inhibitors (ACEIs) are prodrugs activated by carboxylesterase 1 (CES1). We investigated the prognostic importance of CES1 gene (CES1) copy number variation and the rs3815583 single-nucleotide polymorphism in CES1 among ACEI-treated patients with congestive heart failure (CHF).

METHODS: Danish patients with chronic CHF enrolled in the previously reported Echocardiography and Heart Outcome Study were categorized according to their CES1 variants and followed up for up to 10 years. Risk for cardiovascular death and all-cause death was modeled by Cox proportional hazard analyses.

RESULTS: A total of 491 ACEI-treated patients were included in the analyses. After a mean follow-up of 5.5 years, we found no difference in the risk for cardiovascular death and all-cause death between patients having three [hazard ratios (HRs) 1.06 (95% confidence interval (CI) 0.77-1.45) and 1.16 (95% CI 0.88-1.52)] or four [HRs 0.88 (95% CI 0.39-2.01) and 1.37 (95% CI 0.74-2.54)] CES1 copies and those with two copies, respectively. Similarly, no difference in the risk for cardiovascular and all-cause death was found for patients heterozygous [HRs 0.91 (95% CI 0.70-1.19) and 0.88 (95% CI 0.69-1.12)] or homozygous [HRs 0.58 (95% CI 0.30-1.15) and 0.82 (95% CI 0.48-1.39)] for the rs3815583 minor allele versus patients homozygous for the major allele. The active promoter of CES1A2 and the rs71647871 single-nucleotide polymorphism minor allele were detected at very low frequencies.

CONCLUSION: This study did not support the use of CES1 copy number variation or rs3815583 as a predictor of fatal outcomes in ACEI-treated patients with CHF.

Original languageEnglish
JournalPharmacogenetics and Genomics
Volume26
Issue number4
Pages (from-to)169-177
Number of pages9
ISSN1744-6872
DOIs
Publication statusPublished - 12 Jan 2016

ID: 49589886